Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Accured Expenses: 2015-2025

Historic Change in Accured Expenses for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Sep 2025 value amounting to $1.1 million.

  • Syndax Pharmaceuticals' Change in Accured Expenses fell 94.76% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 87.68%. This contributed to the annual value of $19.1 million for FY2024, which is 28.73% up from last year.
  • According to the latest figures from Q3 2025, Syndax Pharmaceuticals' Change in Accured Expenses is $1.1 million, which was down 93.84% from $17.9 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' 5-year Change in Accured Expenses high stood at $21.0 million for Q3 2024, and its period low was -$9.2 million during Q1 2023.
  • In the last 3 years, Syndax Pharmaceuticals' Change in Accured Expenses had a median value of $2.4 million in 2023 and averaged $4.6 million.
  • Data for Syndax Pharmaceuticals' Change in Accured Expenses shows a peak YoY increase of 9,304.88% (in 2022) and a maximum YoY decrease of 893.81% (in 2022) over the last 5 years.
  • Over the past 5 years, Syndax Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $638,000 in 2021, then soared by 1,618.81% to $11.0 million in 2022, then crashed by 31.58% to $7.5 million in 2023, then soared by 55.34% to $11.7 million in 2024, then slumped by 94.76% to $1.1 million in 2025.
  • Its Change in Accured Expenses stands at $1.1 million for Q3 2025, versus $17.9 million for Q2 2025 and -$2.5 million for Q1 2025.